Mission
The Mission of RoPlaVac is:
• to establish an internationally recognized new paradigm in malaria vaccination.
• to develop a vaccine against malaria that can simultaneously protect against the two major species of malaria-causing parasites.
• to provide this vaccine at affordable prices to the populations in malaria-endemic regions.
• to establish an internationally recognized new paradigm in malaria vaccination.
• to develop a vaccine against malaria that can simultaneously protect against the two major species of malaria-causing parasites.
• to provide this vaccine at affordable prices to the populations in malaria-endemic regions.
The RoPlaVac Project aims to develop and validate a novel vaccination strategy against malaria, one of the world's deadliest diseases.
Awards
2014 - EVERIS Entrepreneurs Award, Grand Finalist, April 2014, Madrid, Spain. Photo here
2013 - National BES Innovation Contest, 1st Prize for the Health Track and Winner of the Grand Prize, Concurso Nacional de Inovação do Banco Espirito Santo, November 2013, Lisboa, Portugal. Photo 1 here; Photo 2 here
2013 - Building Global Innovators - ISCTE-IUL MIT-Portugal Venture Competition, Honorary Mention Health Track, November 2013, Lisboa, Portugal. Photo here
Patents
RoPlaVac holds the rights to patent Genetically modified rodent Plasmodium parasites as platforms for a whole-organism malaria vaccine. See here for further details and the image on the right for a graphical abstract.
Legal support for patent-related matters by Garrigues.
Media
Media
RoPlaVac is supported by
RoPlaVac is supported by
